论文部分内容阅读
目的:评价黛力新改善脑卒中后抑郁状态及神经功能缺损的疗效。方法:计算机检索Pub Med、Cochrane Library、CNKI、Wan Fang和VIP等数据库,全面搜集黛力新治疗卒中后抑郁的随机对照试验,采用Rev Man 5.0软件对多个研究结果进行Meta分析。结果:共纳入10个试验(809例患者),所有试验均对HAMD进行评分,结果显示黛力新改善卒中后抑郁状态优于对照组[WMD=-5.26,95%CI(-6.45,-4.07)];9个试验对患者NIHSS进行评分,结果显示黛力新改善脑卒中后患者神经功能缺损优于对照组[WMD=-4.33,95%CI(-5.90,-2.75)]。结论:黛力新改善脑卒中后患者抑郁状态及神经功能缺损有效。
Objective: To evaluate the efficacy of Deanxit in improving post-stroke depression and neurological deficits. METHODS: The databases of Pub Med, Cochrane Library, CNKI, Wan Fang and VIP were searched by computer. A comprehensive randomized controlled trial of Deancare on post-stroke depression was conducted. Meta-analysis was performed on several studies using Rev Man 5.0 software. RESULTS: A total of 10 trials (809 patients) were enrolled. All trials rated HAMD. Dextromethorphan showed better post-stroke depression than controls [WMD = -5.26,95% CI (-6.45, -4.07 ). Nine trials scored NIHSS in patients. The results showed that Deanxit improved the neurological deficits in patients with stroke better than those in the control group [WMD = -4.33,95% CI (-5.90, -2.75)]. Conclusion: Deanxit is effective in reducing the depression and neurological deficits in patients after stroke.